(Q36967144)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Guillaume Cartron

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Vincent Delwail

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Gilles Salles

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

2

Roch Houot

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

3

Franck Morschhauser

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

4

Anne Sonet

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

Groupe d'Etude des Lymphomes de l'Adulte (GELA)

19

object named as

Groupe d'Etude des Lymphomes de l'Adulte (GELA)

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

11

Catherine Sebban

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

14

Steven Le Gouill

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

9

Christophe Fermé

1 reference

29 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

Pauline Brice

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Karim Belhadj

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Bruno Audhuy

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Pierre Feugier

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Hervé Maisonneuve

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sophie Lefort

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Nicole Brousse

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Charles Foussard

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

3 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1107-1114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

29 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Natural history of and therapy for the indolent non-Hodgkin's lymphomas.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Improved survival of follicular lymphoma patients in the United States.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Follicular lymphoma international prognostic index.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696615

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of

4 December 2018

1 reference

12 December 2020

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

12 December 2020

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center

1 reference

12 December 2020

Meta-analysis to evaluate the role of interferon in follicular lymphoma

1 reference

12 December 2020

Improved survival for patients with follicular lymphoma

1 reference

12 December 2020

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center

1 reference

12 December 2020

10.3324/HAEMATOL.2012.082412

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

PubMed publication ID

23645690

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23645690%20AND%20SRC:MED&resulttype=core&format=json